Related Experiment Video

Updated: Sep 5, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Elisa Bertoli1,2, Elisa De Carlo1, Alessandro Del Conte1

  • 1Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

International Journal of Molecular Sciences
|July 9, 2022
PubMed

Insights

Osimertinib is a key treatment for EGFR-mutated non-small cell lung cancer (NSCLC). This review explores resistance mechanisms and future therapies for patients who develop resistance to osimertinib.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Osimertinib is a preferred first-line and standard second-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC).
  • While effective, acquired resistance to osimertinib inevitably develops in patients.
  • Understanding resistance mechanisms is critical for managing treatment progression.

Purpose of the Study:

  • To review emerging molecular resistance mechanisms in EGFR-mutated NSCLC after osimertinib treatment.
  • To discuss potential future therapeutic strategies for patients progressing on osimertinib.

Main Methods:

  • Comprehensive literature review.
  • Analysis of published studies on osimertinib resistance in NSCLC.

Main Results:

  • Identified key secondary molecular resistance mechanisms.
  • Highlighted the clinical implications of these resistance pathways.

Conclusions:

  • Resistance to osimertinib is a significant clinical challenge in EGFR-mutated NSCLC.
  • Further research into novel therapeutic approaches is essential to overcome resistance and improve patient outcomes.
Keywords:
EGFR-mutatedNSCLCacquired resistanceosimertinib

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K